Cumberland Pharmaceuticals (NASDAQ:CPIX) Coverage Initiated at StockNews.com

Stock analysts at StockNews.com assumed coverage on shares of Cumberland Pharmaceuticals (NASDAQ:CPIX) in a research note issued on Monday. The brokerage set a “hold” rating on the specialty pharmaceutical company’s stock.

Cumberland Pharmaceuticals Stock Down 4.0 %

Shares of Cumberland Pharmaceuticals stock opened at $1.69 on Monday. The business has a fifty day simple moving average of $1.95 and a 200 day simple moving average of $1.90. The stock has a market cap of $23.96 million, a PE ratio of -3.84 and a beta of 0.16. The company has a quick ratio of 1.11, a current ratio of 1.28 and a debt-to-equity ratio of 0.44. Cumberland Pharmaceuticals has a 12 month low of $1.43 and a 12 month high of $2.36.

Cumberland Pharmaceuticals (NASDAQ:CPIX) last posted its earnings results on Tuesday, March 5th. The specialty pharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter. The company had revenue of $9.35 million for the quarter. Cumberland Pharmaceuticals had a positive return on equity of 6.84% and a negative net margin of 15.87%.

Institutional Trading of Cumberland Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in CPIX. Bank of New York Mellon Corp acquired a new position in Cumberland Pharmaceuticals in the third quarter valued at about $142,000. Acadian Asset Management LLC grew its position in shares of Cumberland Pharmaceuticals by 27.8% in the 1st quarter. Acadian Asset Management LLC now owns 188,243 shares of the specialty pharmaceutical company’s stock valued at $529,000 after purchasing an additional 40,949 shares during the period. Renaissance Technologies LLC increased its stake in Cumberland Pharmaceuticals by 6.3% during the 1st quarter. Renaissance Technologies LLC now owns 644,763 shares of the specialty pharmaceutical company’s stock worth $1,818,000 after purchasing an additional 38,100 shares in the last quarter. Finally, Millennium Management LLC acquired a new stake in Cumberland Pharmaceuticals during the 4th quarter worth approximately $46,000. Institutional investors and hedge funds own 15.51% of the company’s stock.

Cumberland Pharmaceuticals Company Profile

Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.